Interventions for preventing non-melanoma skin cancers in high-risk groups

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Bath Hextall, Fiona ^a   Leonardi Bee, J ^b   Somchand, N ^b   Webster, A ^b   Delitt, J ^b   Perkins, W ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NONE

Author keywords

Carcinoma, basal cell etiology; *prevention control ; Carcinoma, squamous cell etiology; *prevention control ; Neoplasms, radiation induced prevention control ; Randomized controlled trials as topic; Risk factors

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; DEOXYRIBONUCLEASE (PYRIMIDINE DIMER); ETRETIN; ISOTRETINOIN; LIPOSOME; PLACEBO; RETINOL; SELENIUM;

CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET RESTRICTION; DRUG FORMULATION; GRAFT RECIPIENT; HIGH RISK POPULATION; HUMAN; KIDNEY GRAFT; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN CANCER; SKIN DISEASE; UNSPECIFIED SIDE EFFECT; XENODERMA PIGMENTOSUM;

EID: 44949123616     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005414.pub2     Document Type: Review

References (99)

1. Black 1995 {published data only} Black HS, Thornby JI, Wolf JE, Goldberg LH, Herd A, Rosen T, et al.Evidence that a low-fat diet reduces the occurrence of nonmelanoma skin cancer. International Journal of Cancer 1995;62:165-9.
2. Bouwes Bavinck 1995 {published data only} Bouwes Bavinck JN, Tieben LM, Van Der Woude FJ, Tegzess AM, Hermans J, Schegget JT, et al.Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: A double-blind , placebo-controlled study. Journal of Clinical Oncology 1995;13:1933-8.
3. Clark 1996 {published data only} *Clark LC, Combs GF, Turnbull BW, Slate EH for the Nutritional Prevention of Cancer Study Group. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 1996;276(24):1957-1963.
4. Combs GF, Clark LC, Turnbull BW. Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences 1997;10(2-3):227-34.
5. Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomised trial. Journal of the National Cancer Institute 2003;95(19):1477-81.
6. de Sevaux 2003 {published data only} de Sevaux RGL, Smit JV, de Jong EMGJ, van de Kerkhof PCM, Hoitsma AJ. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. Journal of the American Academy of Dermatology 2003;49:407-12.
7. George 2002 {published data only} George R, Weightman W, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australasian Journal of Dermatology 2002;43:269-73.
8. Greenberg 1990 {published data only} Greenberg ER, Baron JA, Stevens MM, Skukel TA, and the skin cancer prevention study group. The skin cancer prevention study: design of a clinical trial of beta-carotene among persons at high risk for non melanoma skin cancer. Controlled Clinical Trials 1989;10:153-66.
9. *Greenberg ER, Baron JA, Stukel TA, Stevens MM, Mandel JS, Spencer SK, et al.A clinical trial of beta carotene to prevent basal cell and squamous-cell cancers of the skin. New England Journal of Medicine 1990;323:789-95.
10. Levine 1997 {published data only} *Levine N, Moon TE, Cartmel B, Bangert JL, for the Southwest Skin Cancer Prevention Study Group. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Cancer Epidemiology, Biomarkers and Prevention 1997;6:957-61.
11. Moon TE, Levine N, Cartmel B, Bangert J, Rodney S, Schreiber M, et al.Design and recruitment for retinoid skin cancer prevention (SKICAP) trials. Cancer Epidemiology, Biomarkers and Prevention 1995;4:661-9.
12. Moon 1997 {published data only} Moon TE, Levine N, Cartmel B, Bangert J, Rodney S, Schreiber M, et al.Design and recruitment for retinoid skin cancer prevention (SKICAP) trials. Cancer Epidemiology, Biomarkers and Prevention 1995;4:661-9.
13. *Moon TE, Levine N, Cartmel B, Bangert JL, Rodney S, Dong Q, et al.Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: A randomized, double-blind , controlled trial. Cancer Epidemiology, Biomarkers and Prevention 1997;6:949-56.
14. Tangrea 1992 {published data only} Tangrea J, Edwards B, Hartman A, Taylor P, and the ISO-BCC Study Group. Isotretinoin-Basal Cell Carcinoma Prevention Trial. Controlled Clinical Trials 1990;11(6):433-50.
15. *Tangrea JA, Edwards BK, Taylor PR, Hartmen AM, and the other members of the Isotretinoin-Basal Cell Carcinoma Study Group. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: A multicenter clinical trial. Journal of the National Cancer Institute 1992;84:328-32.
16. Trangrea JA, Adrianza E, Helsel WE, Taylor PR, Hartman AM, Peck GL, et al.Clinical and Laboratory adverse effects associated with long-term, low-dose isotretinoin:incidence and risk factors. The Isotretinoin-Basal Cell Carcinoma study Group. American Society of Preventive Oncology 1993;2(4): 375-80.
17. Yarosh 2001 {published data only} Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P, for the Xeroderma Pigmentosum Study Group. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. The Lancet 2001;357:926-9.
18. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, et al.Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998;351:623-8.
19. de Graaf 2006 de Graaf YGL, Kennedy C, Wolterbeek R, Collen AFS, Willemze R, Bouwes Bavinck JN. Photodynamic therapy does ot prevent cutaneous squamous cell carcinoma in organ - transplant recipients: results of a randomized-controlled trial. Journal of Investigative Dermatology 2006;126:569-74.
20. Einspahr 2002 Einspahr JG, Nelson MA, Saboda K, Warneke J, Bowden GT, Alberts DS. Modulation of biologic end points by topical difluoromethylornithine (DFMO), in subjets at high-risk of nonmelanoma skin cancer. Clinical Cancer Research 2002;8:149-55.
21. Frieling 2001 Frieling UM, Schaumberg DA, Kupper TS, Muntwyler J, Hennekens CH. A randomized, 12- year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the Physicians' Health Study. Arch Dermatol 2000;136(2):179-84.
22. Green 1994 Green A, Battistutta D, Hart V, Leslie D, Marks G, Williams G, et al.The Nambour Skin Cancer and Actinic Eye Disease Prevention Trial: design and baseline characteristics of participants. Controlled Clinical Trials 1994;15(6):512-22.
23. Neale 2002 Neal R, Williams G, Green A. Application patterns among participants randomized to daily sunscreen use in a skin cancer prevention trial. Archives of Dermatology 2002;138:1319-25.
24. Shigaki 2002 Shigaki D, Maddock JE, Isnec MR. A randomized trial of skin cancer prevention in aquatics settings: The Pool Cool Program. Health Psychology 2002;21(6):579-87.
25. Pittelkow Randomised study of acitretin in patients with multiple prior skin cancers who received solid organ transplantation.. Ongoing study Starting date of trial not provided. Contact author for more information.
26. ACS 2003 ACS. Cancer facts and figures 2003. American Cancer Society.
27. AIHW2003 AIHW. Media release: higher risk of cancer for men. Australian Health and Welfare Institute.
28. Alam 2001 Alam M, Ratner D. Cutaneous squamous-cell carcinoma. New England Journal of Medicine 2001;344(13):975-83.
29. Alexis 1999 Alexis AF, Jones VA, Stiller MJ. Potential therapeutic applications of tea in dermatology. International Journal of Dermatology 1999;38(10):735-43.
30. Altman 1991 Altman DG. Practical statistics for medical research. London: Chapman and Hall, 1991.
31. Auerbach 1961 Auerbach H. Geographic variation in incidence of skin cancer in the United States. Public Health Reports 1961;76:345-8.
32. Bath-Hextall 2004 Bath-Hextall F, Bong J, Perkins W, Williams HC. Interventions for basal cell carcinoma of the skin: systematic review. BMJ 2004;329:705-8.
33. Bavinck 1995 Bavinck JN, Tieben LM, Van der Woude FJ, Tegzess AM, Hermans J, ter Schegget J, et al.Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. Journal of Clinical Oncology 1995;13(8):1933-8.
34. Bialy 2002 Bialy T, Rothe M, Grant-Kels J. Dietary factors in the prevention and treatment of nonmelanoma skin cancer and melanoma. Dermtological Surgery 2002;28(12):1143-52.
35. Black 1998 Black HS. Influence of dietary factors on actinically-induced skin cancer. Mutation Research 1998;422(1): 185-90.
36. Buettner 1993 Buettner GR. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Archives of Biochemistry and Biophysics 1993;300(2):535-43.
37. Cartmel 2000 Cartmel B, Moon TE, Levine N, Rodney S, Alberts D. Predictors of inactivation and reasons for participant inactivation during a skin cancer chemoprevention study. Cancer Epidemiology Biomarkers Prevention 2000;9:999-1002.
38. Cox 1999 Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen's disease. British Association of Dermatologists. British Journal of Dermatology 1999;141(4):633-41.
39. CRUK 2004 CRUK. Skin cancer - non-melanoma. http://www.cruk.org.uk 2004.
40. Demopoulos 2003 Demopoulos BP, Vamvakas E, Ehrlich JE, Demopoulos R. Nonacquired immunodeficiency syndrome-defining malignancies in patients infected with human immunodeficiency virus. Archives of Pathology and Laboratory Medicine 2003;127(5):589-92.
41. DiGiovanna 1995 DiGiovanna JJ, Sollitto RB, Abangan DL, Steinberg SM, Reynolds JC. Osteoporosis is a toxic effect of long-term etretinate therapy. Archives of Dermatology 1995;131(11):1263-7.
42. DiGiovanna 2001 DiGiovanna JJ. Isotretinoin effects on bone. Journal of the American Academy of Dermatology 2001;45(5):S176-82.
43. Dinehart 1996 Dinehart SM, Jansen GT. Cancer of the skin. In: MyersEN, SuenJY editor(s). Cancer of the Head and Neck. 3rd Edition. WB Saunders Company, 1996:143-159.
44. Duffield-Lillico Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomised trial. Journal of the National Cancer Institute 2003;95(19):1477-81.
45. Dunnick 1991 Dunnick JK, Forbes PD, Eustis SL, Hardisty JF, Goodman DG. Tumors of the skin in the HRA/Skh mouse after treatment with 8-methoxypsolaren and UVA radiation. Fundamental and Applied Toxicology 1991;16:92-102.
46. Eedy 2000 Eedy DJ. Non-melanoma skin cancer and the 'new National Health Service': implications for U.K. dermatology?. British Journal of Dermatology 2000;142(3):397-9.
47. Fine 1999 Fine JD, Johnson LB, Suchidran C, Bauer EA, Carter DM, McGuire J. Cancer and inherited epidermolysis bullosa registry study population. In: FineJD, BauerEA, McGuireJ, MoshellA editor(s). Epidermolysis bullosa: clinical, epidemiologic, and laboratory advances, and the findings of the national epidermolysis bullosa registry. Baltimore: John Hopkins University Press, 1999:175-92.
48. Fine 2004 Fine J, Johnson LB, Weiner M, Stein A, Suchindran C. Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: Results of a phase 1 trial of systemic isotretinoin. Journal of the American Academy of Dermatology 2004;50(4):563-71.
49. Fuller 1992 Fuller CJ, Faulkner H, Bendich A, Parker RS, Roe DA. Effect of beta-carotene supplementation on photosuppression of delayed-type hypersensitivity in normal young men. American Journal of Clinical Nutrition 1992;56(4):684-90.
50. Gasparro 1998 Gasparro FP, Mitchnick M, Nash JF. A review of sunscreen safety and efficacy. Photochemistry and photobiology 1998;68(3):243-56.
51. Gensler 1996 Gensler HL, Aickin M, Peng YM, Xu M. Importance of the form of topical vitamin E for prevention of photocarcinogenesis. Nutrition and Cancer 1996;26(2):183-91.
52. Glass 1989 Glass AG, Hoover RN. The emerging epidemic of melanoma and squamous cell skin cancer. Journal of the American Medical Association 1989;262(15):2097-100.
53. Goldman 1998 Goldman GD. Squamous cell cancer: a practical approach. Seminars in Cutaneous Medicine and Surgery 1998;17(2): 80-95.
54. Gray 1997 Gray DT, Suman VJ, Su WP, Clay RP, Harmsen WS, Roenigk RK. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Archives in Dermatology 1997;133(6):735-40.
55. Green 1999 Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, et al.Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999;354(9180):723-9.
56. Grossman 1997 Grossman D, Leffell DJ. The molecular basis of nonmelanoma skin cancer: new understanding. Archives in Dermatology 1997;133(10):1263-70.
57. Hardie 1980 Hardie IR, Strong RW, Hartley LC, Woodruff PW, Clunie GJ. Skin cancer in Caucasian renal allograft recipients living in a subtropical climate. Surgery 1980;87(2):177-83.
58. Harris 2001 Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. Journal of the American Academy of Dermatology 2001;45(4):528-36.
59. Hartevelt 1990 Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990;49(3):506-9.
60. Heyman 1956 Heyman A, Pfeiffer JB Jr, Willett RW, Taylor HM. Peripheral neuropathy caused by arsenical intoxication; a study of 41 cases with observations on the effects of BAL (2, 3, dimercapto-propanol). New England Journal of Medicine 1956;254(9):401-9.
61. Holme 2000 Holme SA, Malinovszky K, Roberts DL. Changing trends in nonmelanoma skin cancer in South Wales, 1988-98. British Journal of Dermatology 2000;143(6):1224-9.
62. Hughes 1983 Hughes GS, Jr. Davis L. Variegate porphyria and heavymetal poisoning from ingestion of "moonshine". Southern Medical Journal 1983;76(8):1027-9.
63. Iversen 1999 Iversen T, Tretli S. Trends for invasive squamous cell neoplasia of the skin in Norway. British Journal of Cancer 1999;81(3):528-31.
64. Jaax 1997 Jaxx S, Scott LW, Wolf JE, Thornby JL, Black HS. General guidelines for a low-fat diet effective in the management and prevention of nonmelanoma skin cancer. Nutrition and Cancer 1997;27:150-6.
65. Johnson 1996 Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, et al.Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996;272(5268):1668-71.
66. Juni 2001 Juni P, Altman DG, Egger M. Assessing the qualtity of controlled clinical trials. British Medical Journal 2001;323:42-6.
67. Karagas 2006 Karagas MR, Nelson HH, Sehr P, Waterboer T, et al.Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. Journal of the National Cancer Institute 2006;98(6):389-95.
68. Kraemer 1980 Kraemer KH. Xeroderma pigmentosum. A prototype disease of environmental-genetic interaction. Archives in Dermatology 1980;116(5):541-2.
69. Kraemer 1994 Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Archives in Dermatology 1994;130(8):1018-21.
70. Lang 1991 Lang PG, Maize JC. Basal Cell Carcinoma. In: FriedmanRJ, Rigel, KopfAW, HarrisMN, BakerD editor(s). Cancer of the skin. WB Saunders Company, 1991:35-73.
71. Lippman 1987 Lippman SM, Kessler JF, Meyskens FL Jr. Retinoids as preventive and therapeutic anticancer agents (Part I). Cancer Treatment Reports 1987;71(4):391-405.
72. Lookingbill 1995 Lookingbill DP, Lookingbill GL, Leppard B. Actinic damage and skin cancer in albinos in northern Tanzania: findings in 164 patients enrolled in an outreach skin care program. Journal of the American Academy of Dermatology 1995;32(4):653-8.
73. Marcil 2000 Marcil I, Stern R. Risk of developing a subsequent non-melanoma skin cancer in patients with a history of non-melanoma skin cancer: A critical review of the literature and meta analysis. Archives of Dermatology 2000;136:1524.
74. Martinez 2001 Martinez JC, Otley CC. The management of melanoma and nonmelanoma skin cancer: a review for the primary care physician. Mayo Clinic Proceedings 2001;76(12):1253-65.
75. May 1981 May GS, Demets DL, Friedman LM, Furberg C, Passamani E. The randomized clinical trial:bias in analysis. Circulation 1981;64:669-73.
76. McCormack 1997 McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma. A possible indicator of differing causes. Archives of Dermatology 1997;133(5):593-6.
77. McVean 1999 McVean M, Liebler DC. Prevention of DNA photodamage by vitamin E compounds and sunscreens: roles of ultraviolet absorbance and cellular uptake. Molecular Carcinogenesis 1999;24(3):169-76.
78. Naldi 2004 Naldi L, Buzzetti R, Cecchi C, Baldwin L, Battistutta D, Benvenuto C, et al.Educational programmes for the skin cancer prevention (Protocol for a Cochrane Review). Cochrane Database of Systematic Reviews 2004, Issue 2.
79. Naylor 1997 Naylor MF, Farmer KC. The case for sunscreens: a review of their use in preventing actinic damage and neoplasia. Archives of Dermatology 1997;133(9):1146-54.
80. NCCN 2004 National Comprehensive Cancer Network (NCCN). Guidelines for the treatment of basal and squamous skin cancers. http://www.nccn.org/ physician_gls/f_guidelines.html Accessed 13 July 2004.
81. Neubauer 1947 Neubauer O. Arsenical Cancer: a review. British Journal of Cancer 1947;1:192-251.
82. Parrish 1974 Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and long wave ultraviolet light. New England Journal of Medicine 1974;291:1207-11.
83. Peck 1982 Peck GL, Gross EG, Butkus D, DiGiovanna JJ. Chemoprevention of basal cell carcinoma with isotretinoin. Journal of the American Academy of Dermatology 1982;6(4 Pt 2 Suppl):815-23.
84. Peck 1988 Peck GL, DiGiovanna JJ, Sarnoff DS, Gross EG, Butkus D, Olsen TG, et al.Treatment and prevention of basal cell carcinoma with oral isotretinoin. Journal of American Academy of Dermatology 1988;19(1Pt 2):176-85.
85. Pence 1994 Pence BC, Delver E, Dunn DM. Effects of dietary selenium on UVB induced skin carcinogenesis and epidermal antioxidant status. Journal of Investigative Dermatology 1994;102(5):759-61.
86. Pershagen 1981 Pershagen G. The carcinogenicity of arsenic. Environmental Health Perspectives 1981;40:93-100.
87. Rosenberg 2004 Rosenberg C, Greenland P, Khandekar J, Loar A, Ascensao J, Lopez A. Association of nonmelanoma skin cancer with second malignancy. Cancer 2004;100(1):130-8.
88. Rowe 1992 Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. Journal of the American Academy of Dermatology 1992;26(6):976-90.
89. Sackett 1979 Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. New England Journal of Medicine 1979;301:1410-12.
90. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ. Empirical evidence of bias. Journal of the American Medical Academy 1995;273:408-12.
91. Schwartz 1997 Schwartz RA. Arsenic and the skin. International Journal of Dermatology 1997;36(4):241-50.
92. Shindo 1993 Shindo Y, Witt E, Packer L. Antioxidant defense mechanisms in murine epidermis and dermis and their responses to ultraviolet light. Journal of Investigative Dermatology 1993;100(3):260-5.
93. Staples 1998 Staples M, Marks R, Giles G. Trends in the incidence of nonmelanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs starting to have an effect?. International Journal of Cancer 1998;78(2):144-8.
94. Stern 1998 Stern RS, Liebman EJ, Vakeva L. Oral psolaren and ultraviolet-A Light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. Journal of the National Cancer Institute 1998;90(17):1278-84.
95. Stern 1999 Stern RS. The mysteries of geographic variability in nonmelanoma skin cancer incidence. Archives of Dermatology 1999;135(7):843-4.
96. Telfer 1999 Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. British Association of Dermatologists. British Journal of Dermatology 1999;141(3):415-23.
97. Treleaven 1993 Treleaven J, Meller S, Farmer P, Birchall D, Goldman J, Piller G. Arsenic and ayurveda. Leukemia and Lymphoma 1993;10(4-5):343-5.
98. Westby 2004 Westby M, Bath FJ, Herd R, Macnell SJ. Photodynamic therapy for the localised squamous cell carcinoma of the skin (Protocol for a Cochrane Review). Cochrane Database of Systematic Reviews 2003, Issue 2.
99. Wong 2003 Wong C, Strange R, Lear J. Basal cell carcinoma. BMJ 2003;327:794.